DE69816325D1 - Gepufferte arzneistoffformulierungen zur transdermalen verabreichung durch elektrotransport - Google Patents

Gepufferte arzneistoffformulierungen zur transdermalen verabreichung durch elektrotransport

Info

Publication number
DE69816325D1
DE69816325D1 DE69816325T DE69816325T DE69816325D1 DE 69816325 D1 DE69816325 D1 DE 69816325D1 DE 69816325 T DE69816325 T DE 69816325T DE 69816325 T DE69816325 T DE 69816325T DE 69816325 D1 DE69816325 D1 DE 69816325D1
Authority
DE
Germany
Prior art keywords
transdermal administration
drug formulations
electro transport
buffered drug
buffered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69816325T
Other languages
English (en)
Other versions
DE69816325T2 (de
Inventor
Ka Leung
J Cormier
Lee Sendelbeck
Anna Muchnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of DE69816325D1 publication Critical patent/DE69816325D1/de
Application granted granted Critical
Publication of DE69816325T2 publication Critical patent/DE69816325T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A61N1/0416—Anode and cathode
    • A61N1/0424—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0444—Membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69816325T 1997-11-12 1998-11-03 Gepufferte arzneistoffformulierungen zur transdermalen verabreichung durch elektrotransport Expired - Lifetime DE69816325T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96921797A 1997-11-12 1997-11-12
US969217 1997-11-12
PCT/US1998/023411 WO1999024015A1 (en) 1997-11-12 1998-11-03 Buffered drug formulations for transdermal electrotransport delivery

Publications (2)

Publication Number Publication Date
DE69816325D1 true DE69816325D1 (de) 2003-08-14
DE69816325T2 DE69816325T2 (de) 2004-04-22

Family

ID=25515320

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69816325T Expired - Lifetime DE69816325T2 (de) 1997-11-12 1998-11-03 Gepufferte arzneistoffformulierungen zur transdermalen verabreichung durch elektrotransport
DE69826705T Expired - Lifetime DE69826705T2 (de) 1997-11-12 1998-11-03 Verfahren zur dermalen verabreichung von polypeptiden

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69826705T Expired - Lifetime DE69826705T2 (de) 1997-11-12 1998-11-03 Verfahren zur dermalen verabreichung von polypeptiden

Country Status (9)

Country Link
US (2) US20020058608A1 (de)
EP (2) EP1028706B1 (de)
JP (2) JP2001522793A (de)
CN (1) CN1278737A (de)
AU (2) AU1302499A (de)
CA (2) CA2309818C (de)
DE (2) DE69816325T2 (de)
ES (2) ES2202910T3 (de)
WO (2) WO1999024071A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1180121T1 (en) 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
AU2002233089B2 (en) 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
ITMI20030755A1 (it) * 2003-04-11 2004-10-12 Bottega Verde S R L Peptidi e loro derivati quali inibitori di fenomeni degradativi e composizioni contenenti gli stessi.
DE602004010246T2 (de) * 2003-04-25 2008-05-29 Ajinomoto Co., Inc. Neues glycopeptid oder peptid, das dazu fähig ist, geschmacksreichtum zu verleihen, und verfahren, bei dem man nahrungsmitteln damit reichen geschmack verleiht
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
JP2007519613A (ja) * 2003-10-23 2007-07-19 アルザ・コーポレーシヨン 微小突出部をコーティングするための安定化されたｄｎａの組成物
ATE387240T1 (de) * 2003-11-19 2008-03-15 Alza Corp Peptidisch gepufferte formulierungen für elektrotransport-anwendungen und zugehörige herstellungsverfahren
JPWO2006093222A1 (ja) * 2005-03-02 2008-08-07 味の素株式会社 インスリンの多量体形成阻害剤
US9616011B2 (en) 2005-04-27 2017-04-11 The Procter & Gamble Company Personal care compositions
US20070020220A1 (en) * 2005-04-27 2007-01-25 Procter & Gamble Personal care compositions
AU2014271339B2 (en) * 2005-04-27 2016-11-03 The Procter & Gamble Company Personal care compositions
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
EP2049149B1 (de) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylierte verlängerte insuline
JP5864834B2 (ja) 2006-09-22 2016-02-17 ノボ・ノルデイスク・エー／エス プロテアーゼ耐性のインスリンアナログ
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US20100120660A1 (en) * 2007-04-30 2010-05-13 Per Balschmidt Highly concentrated insulin solutions and compositions
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
JP2009067766A (ja) * 2007-09-12 2009-04-02 Kosumedei Seiyaku Kk 経皮吸収促製剤及びそれを用いた経皮吸収システム
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
PT2254906T (pt) 2008-03-18 2017-01-03 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
HUE037735T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
US8361779B2 (en) * 2010-11-24 2013-01-29 Sachem, Inc. Buffer compounds
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ES2566549T3 (es) 2011-06-17 2016-04-13 Halozyme, Inc. Formulaciones estables de enzima degradante de hialuronano
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014012789A2 (pt) * 2011-11-28 2019-09-24 Phasebio Pharmaceuticals Inc agentes terapêuticos compreendendo sequências de aminoácidos de insulina
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
EP2991672A1 (de) 2013-04-30 2016-03-09 Novo Nordisk A/S Neuartiges verabreichungsschema
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN110087674B (zh) 2016-12-16 2023-01-03 诺和诺德股份有限公司 含胰岛素的药物组合物
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
PL3870213T3 (pl) 2018-10-26 2023-11-20 Novo Nordisk A/S Stabilne kompozycje semaglutydu i ich zastosowania

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767401A (en) * 1975-04-22 1988-08-30 Maurice Seiderman Iontophoretic administration of ionizable or polar medicaments to a mammalian body
US4250878A (en) * 1978-11-22 1981-02-17 Motion Control, Inc. Non-invasive chemical species delivery apparatus and method
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4371523A (en) * 1980-12-29 1983-02-01 The Regents Of The University Of California Reducing the aggregation of insulin in solution
US4477391A (en) * 1981-08-14 1984-10-16 Collins James F Amino acid isomers, their production and their medicinal use
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4744819A (en) * 1984-10-23 1988-05-17 Daicel Chemical Industries Ltd. 4-oxo pyridinecarboxamide derivatives as plant growth regulators
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4722726A (en) * 1986-02-12 1988-02-02 Key Pharmaceuticals, Inc. Method and apparatus for iontophoretic drug delivery
US4752285B1 (en) * 1986-03-19 1995-08-22 Univ Utah Res Found Methods and apparatus for iontophoresis application of medicaments
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US5250022A (en) * 1990-09-25 1993-10-05 Rutgers, The State University Of New Jersey Iontotherapeutic devices, reservoir electrode devices therefore, process and unit dose
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
US5032109A (en) * 1987-02-10 1991-07-16 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
US4878892A (en) * 1987-02-10 1989-11-07 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
US4940456A (en) * 1987-02-10 1990-07-10 Dan Sibalis Electrolytic transdermal delivery of proteins
US5080646A (en) * 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5162042A (en) * 1988-07-05 1992-11-10 Alza Corporation Electrotransport transdermal system
US5496266A (en) * 1990-04-30 1996-03-05 Alza Corporation Device and method of iontophoretic drug delivery
US5147296A (en) * 1988-10-03 1992-09-15 Alza Corporation Membrane for electrotransport transdermal drug delivery
US4927408A (en) * 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
US5088977A (en) * 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
AU641631B2 (en) * 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
ATE107517T1 (de) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd Transdermales therapeutisches mittel.
AU6446190A (en) * 1989-09-15 1991-04-18 Rutgers, The State University Of New Jersey Process for inducing analgesia, peptides and therapeutic compositions
EP0429842B1 (de) * 1989-10-27 1996-08-28 Korea Research Institute Of Chemical Technology Vorrichtung zur transdermalen Applikation von Protein- oder Peptid-Medikamenten
US5167616A (en) * 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
EP0522043B1 (de) * 1990-03-30 2003-10-15 Alza Corporation Vorrichtung zur iontophoretischen verabreichung
USH1160H (en) * 1990-11-26 1993-04-06 Iontophoretic delivery of peptides
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
RO111990B1 (ro) * 1991-12-20 1997-04-30 Novo Nordisk As Preparate farmaceutice, continand un hormon de crestere sau un derivat al acestuia, si procedeu de preparare
ES2120477T3 (es) * 1992-01-21 1998-11-01 Macrochem Corp Administracion iontoforetica de medicamentos perfeccionada.
CA2087087C (en) * 1992-01-22 2000-07-18 Burton H. Sage, Jr. Molecules for iontophoretic delivery
US5334038A (en) * 1992-03-27 1994-08-02 International Business Machines Corp. High density connector with sliding actuator
US5312326A (en) * 1992-06-02 1994-05-17 Alza Corporation Iontophoretic drug delivery apparatus
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5533971A (en) * 1993-09-03 1996-07-09 Alza Corporation Reduction of skin irritation during electrotransport
US5387189A (en) * 1993-12-02 1995-02-07 Alza Corporation Electrotransport delivery device and method of making same
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
US5470307A (en) * 1994-03-16 1995-11-28 Lindall; Arnold W. Catheter system for controllably releasing a therapeutic agent at a remote tissue site
US5503632A (en) * 1994-04-08 1996-04-02 Alza Corporation Electrotransport device having improved cathodic electrode assembly
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation

Also Published As

Publication number Publication date
DE69826705D1 (de) 2004-11-04
US20020058608A1 (en) 2002-05-16
CN1278737A (zh) 2001-01-03
JP2001522815A (ja) 2001-11-20
EP1028706A1 (de) 2000-08-23
WO1999024015A1 (en) 1999-05-20
JP2001522793A (ja) 2001-11-20
DE69826705T2 (de) 2006-02-23
ES2230727T3 (es) 2005-05-01
EP1030688A1 (de) 2000-08-30
ES2202910T3 (es) 2004-04-01
EP1028706B1 (de) 2003-07-09
AU1302499A (en) 1999-05-31
WO1999024071A1 (en) 1999-05-20
CA2309955A1 (en) 1999-05-20
CA2309818C (en) 2009-05-05
CA2309818A1 (en) 1999-05-20
DE69816325T2 (de) 2004-04-22
US20070078096A1 (en) 2007-04-05
EP1030688B1 (de) 2004-09-29
AU1375199A (en) 1999-05-31

Similar Documents

Publication Publication Date Title
DE69816325D1 (de) Gepufferte arzneistoffformulierungen zur transdermalen verabreichung durch elektrotransport
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
ATE516812T1 (de) Pharmazeutische formulierungen zur anhaltenden arzneimittelfreisetzung
DE69935681D1 (de) Vorrichtungen zur Medikamentverabreichung
NO20000735D0 (no) Legemiddel leveringsanordning for vedvarende frigivelse
ATE234078T1 (de) Pharmazeutische omeprazol-formulierung
DK1043977T3 (da) Oral farmaceutisk doseringsform baseret på pulserende frigørelse
DK1035833T3 (da) Sammensætning til nasal indgivelse
EE04901B1 (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
NO981638D0 (no) Legemiddel- avgivelsesanordning for to eller flere aktive forbindelser
NO961136D0 (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
NO981146D0 (no) Transcytotiske midler og forsterkere for medikamentleveranser
NO20001375D0 (no) Legemiddelformulering med kontrollert virkestoffrigivning
DE69807768T2 (de) Rapamycin enthaltende Formulierungen zur oralen Verabreichung
DE69827947T2 (de) Rapamycin-formulierungen zur oralen verabreichung
NO20022013L (no) Innretninger for transdermal legemiddellevering
FI960435A (fi) Lääkkeiden transdermaalisen antotapaan tarkoitettu koostumus
NO20003284L (no) Farmasøytisk preparat for oral administrering
DK1140038T3 (da) Transdermalt system til indgivelser af lægemidler
FI970053A (fi) Transdermaalinen lääkeaineen antosysteemi
SE9502453D0 (sv) Drug formulations

Legal Events

Date Code Title Description
8364 No opposition during term of opposition